Global Antibody-oligonucleotide Conjugates (AOCs) Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Antibody-oligonucleotide Conjugates (AOCs) market size will reach US$ 586 million by 2031.
AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.
The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.
The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Regionally, North America accounts for more than 60% of the market share thanks to FDA accelerated approval and biotechnology clusters, while Asia Pacific relies on CDMO companies such as WuXi Biologics to enter the production link. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.
LPI (LP Information)' newest research report, the “Antibody-oligonucleotide Conjugates (AOCs) Industry Forecast” looks at past sales and reviews total world Antibody-oligonucleotide Conjugates (AOCs) sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody-oligonucleotide Conjugates (AOCs) sales for 2025 through 2031. With Antibody-oligonucleotide Conjugates (AOCs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-oligonucleotide Conjugates (AOCs) industry.
This Insight Report provides a comprehensive analysis of the global Antibody-oligonucleotide Conjugates (AOCs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody-oligonucleotide Conjugates (AOCs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-oligonucleotide Conjugates (AOCs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-oligonucleotide Conjugates (AOCs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-oligonucleotide Conjugates (AOCs).
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-oligonucleotide Conjugates (AOCs) market by product type, application, key players and key regions and countries.
Segmentation by Type:
Site-specific Coupling
Random Coupling
Segmentation by Application:
Rare and Genetic Diseases
Cancer Treatment
Central Nervous System Disorders
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Denali Therapeutics
Gennao Bio
ChainGen Bio
Please note: The report will take approximately 2 business days to prepare and deliver.
AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.
The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.
The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Regionally, North America accounts for more than 60% of the market share thanks to FDA accelerated approval and biotechnology clusters, while Asia Pacific relies on CDMO companies such as WuXi Biologics to enter the production link. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.
LPI (LP Information)' newest research report, the “Antibody-oligonucleotide Conjugates (AOCs) Industry Forecast” looks at past sales and reviews total world Antibody-oligonucleotide Conjugates (AOCs) sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody-oligonucleotide Conjugates (AOCs) sales for 2025 through 2031. With Antibody-oligonucleotide Conjugates (AOCs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-oligonucleotide Conjugates (AOCs) industry.
This Insight Report provides a comprehensive analysis of the global Antibody-oligonucleotide Conjugates (AOCs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody-oligonucleotide Conjugates (AOCs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-oligonucleotide Conjugates (AOCs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-oligonucleotide Conjugates (AOCs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-oligonucleotide Conjugates (AOCs).
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-oligonucleotide Conjugates (AOCs) market by product type, application, key players and key regions and countries.
Segmentation by Type:
Site-specific Coupling
Random Coupling
Segmentation by Application:
Rare and Genetic Diseases
Cancer Treatment
Central Nervous System Disorders
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Denali Therapeutics
Gennao Bio
ChainGen Bio
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
97 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Antibody-oligonucleotide Conjugates (AOCs) Key Players
- 4 Antibody-oligonucleotide Conjugates (AOCs) by Regions
- 5 United States
- 6 Europe
- 7 China
- 8 Rest of World
- 9 Market Drivers, Challenges and Trends
- 10 Key Investors in Antibody-oligonucleotide Conjugates (AOCs)
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
